Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q3 2020 · 10-Q
Revenue$476.78M$476.78M+3.4% vs Q3 2019 Net Income$784.80M$784.80M+1,326.0% vs Q3 2019 EPS Diluted$4.01$4.01+1,236.7% vs Q3 2019 Operating Income-$55,941,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$69,636,000+86.8% Margins · derivedOperating margin-11.7%−12.6 pt vs Q3 2019
Net margin164.6%+152.7 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end